CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0508 (clinicaltrials.gov NCT No: NCT00402558)
Title:Alloreactive NK Cells with Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for AML and MDS.
Principal Investigator:Richard E. Champlin
Treatment Agent:Antithymocyte Globulin; Busulfan; Fludarabine
Study Status:Terminated
Study Description:The goal of this clinical research study is to determine the safety and effects
of giving a special kind of immune cells called "alloreactive natural killer
(NK) cells" with high dose chemotherapy and allogeneic hematopoeitic stem cell
transplantation with the goal of defining the maximum tolerated dose of NK
cells. The NK cells will be donated from a relative of yours who has certain
genetic type in their blood called HLA, that almost matches yours. The stem
cells you will receive will come from a separate HLA
matched (HLA A, B, C, DR) relative or unrelated donor. The safety of this
treatment will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:Antithymocyte Globulin
Busulfan
Fludarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:about 28 days
Supported By:N/A
Return Visit:varies from daily immediately post discharge to annually
Home Care:none


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Richard E. Champlin
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults